Kimberly Chess
Family · Meadville, PANPI 1811318611
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 573 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,997, 2.5 times the $1,187 reported in 2021. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 573 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$797
- Neurocrine Biosciences, Inc.$708
- Axsome Therapeutics, Inc.$683
- Otsuka America Pharmaceutical, Inc.$644
- plus $4K from 23 others
What the payments were for
- Food & beverage$9,74899%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 149 | $2,010 |
| Alkermes, Inc. | 66 | $1,201 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $797 |
| Neurocrine Biosciences, Inc. | 35 | $708 |
| Axsome Therapeutics, Inc. | 27 | $683 |
| Otsuka America Pharmaceutical, Inc. | 37 | $644 |
| Lundbeck LLC | 35 | $576 |
| AbbVie | 28 | $492 |
| Vanda Pharmaceuticals Inc. | 22 | $449 |
| Merck | 21 | $365 |
| Johnson & Johnson | 18 | $321 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $319 |
| E.r. Squibb & Sons, L.L.C. | 17 | $270 |
| Corium, LLC | 10 | $183 |
| Sage Therapeutics, LLC | 8 | $170 |
| Eisai Inc. | 11 | $149 |
| Ironshore Pharmaceuticals Inc. | 4 | $83 |
| Novo Nordisk | 4 | $69 |
| Indivior Inc. | 3 | $62 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Tris Pharma Inc | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $23 |
| Neos Therapeutics, LP | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Bioxcel Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$250
How this compares
$9,807 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 27 | $192,844 |
| IngrezzaValbenazine Tosylate | 11 | $87,345 |
| RexultiBrexpiprazole | 37 | $61,473 |
| Abilify MaintenaAripiprazole | 13 | $37,107 |
| Invega SustennaPaliperidone Palmitate | 14 | $33,889 |
| Lurasidone Hcl | 16 | $11,581 |
| TrintellixVortioxetine Hydrobromide | 16 | $7,190 |
| Paliperidone ErPaliperidone | 12 | $3,624 |
| Chlorpromazine Hcl | 25 | $3,142 |
| Duloxetine Hcl | 144 | $2,290 |
| Buspirone Hcl | 144 | $2,106 |
| Aripiprazole | 112 | $2,101 |
| Hydroxyzine Hcl | 113 | $1,888 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $1,500 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 108 | $1,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,010 | $192,84427 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $644 | $98,58050 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $708 | $87,34511 claims |
| Johnson & JohnsonInvega Sustenna | $321 | $33,88914 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $319 | $7,19016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Meadville
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.